HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Semnani, E. S. Articles by Kassis, A. I. Search for Related Content PubMed PubMed Citation Articles by Semnani, E. S. Articles by Kassis, A. I.

5-[¹²³I/¹²⁵I]Iodo-2'-Deoxyuridine in Metastatic Lung Cancer: Radiopharmaceutical Formulation Affects Targeting

Department of Radiology, Harvard Medical School, Boston, Massachusetts

This study assesses targeting of lung metastases in mice with the radioiodinated thymidine analog 5-[¹²³I/¹²⁵I]iodo-2'-deoxyuridine (¹²³I-IUdR/¹²⁵I-IUdR), formulated with varying amounts of tributyltin precursor and injected intravenously. Methods: Six- to 8-wk-old C57BL/6 mice were injected intravenously with B16F10 melanoma cells. Two weeks later, when lung tumors were established, the animals were injected intravenously with ¹²⁵I-IUdR synthesized using 1, 35, 100, 150, 200, or 250 µg 5-tributylstannyl-2'-deoxyuridine (SnUdR) in the presence of an oxidant. Nontumor-bearing mice were also injected with these formulations and served as control animals. Twenty-four hours later, the animals were killed, and the radioactivity associated with the lungs and other tissues was measured in a -counter. The percentage injected dose per gram tissue (%ID/g) and tumor-to-nontumor ratios (T/NT ratios) were calculated. Phosphor imaging was done on lungs from tumor-bearing and nontumor-bearing mice injected with ¹²⁵I-IUdR formulated with each tin precursor concentration. Scintigraphy was also performed 3 and 24 h after intravenous injection of ¹²³I-IUdR. Results: The %ID/g ¹²⁵I-IUdR was higher in lungs of tumor-bearing animals than in lungs of control animals. Although the increase in SnUdR present led to a small but statistically significant decrease in the radioactive content of normal lungs, a 3-fold increase was observed in the lungs of tumor-bearing animals with radiopharmaceutical formulated with 100 µg SnUdR (5 µg per mouse). This enhancement in radioactive uptake by the lungs led to approximately 14-fold increases in T/NT ratios. Phosphor imaging (¹²⁵I-IUdR) of lungs as well as scintigraphy (¹²³I-IUdR) of whole animals substantiated these findings. Conclusion: The formulation for the synthesis of radio-IUdR that leads to the highest %ID/g in tumor and the best T/NT ratio has been identified. Further studies are required to determine the factors responsible for specific enhancement in IUdR tumor uptake.

Key Words: 5-[¹²³I/¹²⁵I]iodo-2'-deoxyuridine • metastatic lung cancer • 5-tributylstannyl-2'-deoxyuridine • tumor targeting

Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]